[Effects of emoxipine, reamberine and mexidol on neuropathic symptoms and a systolic function of the left ventricular myocardium in patients with diabetes mellitus and diabetic foot syndrome].
OBJECTIVE
To compare efficacy of 3-oxypiridine and succinic acid derivatives (emoxipine, reamberine and mexidol) in distal neuropathy (DN) and left ventricular myocardium systolic function (LVMSF) in diabetic patients with diabetic foot syndrome (DFS).


METHODS
We studied 120 patients with diabetes mellitus type 1 and 2 (DM1 and DM2). The patients had neuropathic and neuroischemic forms of DFS (stage 0-1 by Wagner, 1990). The patients were randomized into 4 equal groups matched by gender and number of patients with DM1 and DM2. Group 1 received basic therapy plus intravenous placebo (daily 200 ml drops of the polarizing mixture). Group 2 received additional 150 mg emoxipine. Group 3 was given daily intravenous drop infusions of 400 ml reamberin. Group 4 received once daily 300 mg mexidol. The infusion therapy in all the groups lasted for 14 days. Quantitation of neuropathic symptomatic count (NSC), neuropathic dysfunction count (NDC) and echocardiographic examination of LVMSF were made and venous blood samples were obtained before the treatment and after 2 weeks of therapy.


RESULTS
Emoxipin, reamberin and mexidol therapy alleviated DM symptoms. In contrast to placebo, the drugs lessened the scores by NSC and NDC. By NSC, the lowest total score was observed after treatment with reamberin. LVMSF changed most significantly in patients on emoxipin, less significantly in those on reamberin and insignificantly on mexidol. The above positive effect did not depend on metabolic compensation of DM.


CONCLUSIONS
The addition of emoxipin, reamberin and mexidol to the scheme of DM patients with DFS relieves symptoms of DM. Moreover, reduction of DM symptoms due to emoxipin and reamberin is associated with better LVMSF.
Volchegorskiĭ
I A
IA
Moskvicheva
M G
MG
Chashchina
E N
EN
D000368:Aged; D000975:Antioxidants / Q000627:therapeutic use*; D003922:Diabetes Mellitus, Type 1 / Q000150:complications*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D017719:Diabetic Foot / Q000188:drug therapy*; D004452:Echocardiography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010847:Picolines / Q000627:therapeutic use*; D011446:Prospective Studies; D013386:Succinates / Q000627:therapeutic use*; D013599:Systole / Q000187:drug effects; D013997:Time Factors; D016896:Treatment Outcome; D016277:Ventricular Function, Left / Q000502:physiology*
D000975:Antioxidants; D010847:Picolines; D013386:Succinates; C070020:emoxypine succinate; C009820:6-methyl-2-ethyl-3-hydroxypyridine